The role of roxithromycin in the treatment of respiratory tract infections: a comprehensive overview
DOI:
https://doi.org/10.18203/2320-6012.ijrms20242269Keywords:
URTIs, LRTIs, Roxithromycin, Chronic rhinosinusitis, Post-antibiotic effect, Anti-inflammatory effectAbstract
Respiratory tract infections (RTIs) represent a substantial global health burden. Antibiotics, including macrolides like roxithromycin, are frequently prescribed to treat these infections. Roxithromycin exhibits bacteriostatic and bactericidal properties by disrupting bacterial protein synthesis. It has a better pharmacokinetic profile than erythromycin and demonstrates satisfactory tissue penetration and distribution. In addition to its antimicrobial action, roxithromycin displays anti-inflammatory properties, modulates neutrophilic actions, reduces pro-inflammatory cytokines, and inhibits mucus secretion and synthesis. These mechanisms contribute to its efficacy in treating a spectrum of RTIs, including sinusitis, pharyngotonsillitis, chronic rhinosinusitis, pneumonia, and bronchiectasis. Clinical studies have consistently demonstrated the effectiveness and tolerability of roxithromycin. Overall, roxithromycin offers a multifaceted approach to target both the microbial and inflammatory components of RTIs. Hence, this review aims to provide an overview of the pharmacokinetics and pharmacodynamics, as well as the efficacy and tolerability of roxithromycin in treating RTIs.
References
Rogan M. Respiratory Infections, Acute. Int Encyclopedia Publ Health. 2017;332-6.
Van Eyk AD. Treatment of bacterial respiratory infections. South African Family Practice. 2019;61(2):8-15.
Reed KD. Respiratory Tract Infections: A Clinical Approach. Molecular Med Microbiol. 2015;1499-506.
Cooke J, Llor C, Hopstaken R, Dryden M, Butler C. Respiratory tract infections (RTIs) in primary care: narrative review of C reactive protein (CRP) point-of-care testing (POCT) and antibacterial use in patients who present with symptoms of RTI. BMJ Open Respir Res. 2020;7(1):e000624.
Chen AP, Chuang C, Huang YC, Wu PF, Huang SF, Cheng NC, et al. The epidemiology and etiologies of respiratory tract infection in Northern Taiwan during the early phase of coronavirus disease 2019 (COVID-19) outbreak. J Microbiol Immunol Infect. 2021;54(5):801-7.
Vázquez-Laslop N, Mankin AS. How Macrolide Antibiotics Work. Trends Biochem Sci. 2018;43(9):668-84.
Blondeau JM. Immunomodulatory Effects of Macrolides Considering Evidence from Human and Veterinary Medicine. Microorganisms. 2022;10(12):2438.
Pollock J, Chalmers JD. The immunomodulatory effects of macrolide antibiotics in respiratory disease. Pulm Pharmacol Ther. 2021;71:102095.
Lin X, Lu J, Yang M, Dong BR, Wu HM. Macrolides for diffuse panbronchiolitis. Cochrane Database Syst Rev. 2015;1(1):CD007716.
Markham A, Faulds D. Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994;48(2):297-326.
Young RA, Gonzalez JP, Sorkin EM. Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1989;37(1):8-41.
Roxithromycin. New Zealand Data Sheet. Available at: https://www.medsafe.govt.nz/profs/datasheet/a/ArrowRoxithromycintab.pdf. Accessed on 13 May 2024.
Kuenzi B, Segessenmann C, Gerber AU. Postantibiotic effect of roxithromycin, erythromycin, and clindamycin against selected gram-positive bacteria and Haemophilus influenzae. J Antimicrob Chemother. 1987;20(B):39-46.
Siu J, Klingler L, Wang Y, Hung CT, Jeong SH, Smith S, et al. Oral antibiotics used in the treatment of chronic rhinosinusitis have limited penetration into the sinonasal mucosa: a randomized trial. Xenobiotica. 2020;50(12):1443-50.
Hand WL, King-Thompson N, Holman JW. Entry of roxithromycin (RU 965), imipenem, cefotaxime, trimethoprim, and metronidazole into human polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1987;31(10):1553-7.
Carlier MB, Zenebergh A, Tulkens PM. Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells. J Antimicrob Chemother. 1987;20(B):47-56.
Cervin A, Wallwork B. Efficacy and safety of long-term antibiotics (macrolides) for the treatment of chronic rhinosinusitis. Curr Allergy Asthma Rep. 2014;14(3):416.
Tamaoki J, Takeyama K, Yamawaki I, Kondo M, Konno K. Lipopolysaccharide-induced goblet cell hypersecretion in the guinea pig trachea: inhibition by macrolides. Am J Physiol. 1997;272(1 Pt 1):L15-9.
Tamaoki J. The effects of macrolides on inflammatory cells. Chest. 2004;125(2):41S-50S.
Tamaoki J, Kondo M, Kohri K, Aoshiba K, Tagaya E, Nagai A. Macrolide antibiotics protect against immune complex-induced lung injury in rats: role of nitric oxide from alveolar macrophages. J Immunol. 1999;163(5):2909-15.
Nakamura H, Fujishima S, Inoue T, Ohkubo Y, Soejima K, Waki Y, et al. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J. 1999;13(6):1371-9.
Zimmermann P, Ziesenitz VC, Curtis N, Ritz N. The Immunomodulatory Effects of Macrolides-A Systematic Review of the Underlying Mechanisms. Front Immunol. 2018;9:302.
Shirsat A, Khandke DA, Patankar A. Comparison of the in vitro Sensitivity of Respiratory Pathogens to Roxithromycin, Amoxicillin and Amoxicillin+ Clavulanic Acid. The Indian Practitioner. 2017:11-5.
EUCAST. Available at: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_14.0_Breakpoint_Tables.pdf. Accessed on 5 March 2024.
Tamaoki J, Nakata J, Tagaya E, Konno K. Effects of roxithromycin and erythromycin on interleukin 8-induced neutrophil recruitment and goblet cell secretion in guinea pig tracheas. Antimicrob Agents Chemother. 1996;40(7):1726-8.
Rubin BK. Physiology of airway mucus clearance. Respir Care. 2002;47(7):761-8.
Shimizu T, Shimizu S, Hattori R, Gabazza EC, Majima Y. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am J Respir Crit Care Med. 2003;168(5):581-7.
Chatzimanolis E, Marsan N, Lefatzis D, Pavlopoulos A. Comparison of roxithromycin with co-amoxiclav in patients with sinusitis. J Antimicrob Chemother. 1998;41(B):81-4.
Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest. 2004;125(2):52S-60.
Kimura N, Nishioka K, Nishizaki K, Ogawa T, Naitou Y, Masuda Y. Clinical effect of low-dose, long-term roxithromycin chemotherapy in patients with chronic sinusitis. Acta Med Okayama. 1997;51(1):33-7.
Wallwork B, Coman W, Mackay-Sim A, Greiff L, Cervin A. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscope. 2006;116(2):189-93.
Mira E, Benazzo M. A multicenter study on the clinical efficacy and safety of roxithromycin in the treatment of ear-nose-throat infections: comparison with amoxycillin/clavulanic acid. J Chemother. 2001;13(6):621-7.
de Campora E, Camaioni A, Leonardi M, Fardella P, Fiaoni M. Comparative efficacy and safety of roxithromycin and clarithromycin in upper respiratory tract infections. Diagn Microbiol Infect Dis. 1992;15(4):119S-22S.
Salvarezza CR, Mingrone H, Fachinelli H, Kijanczuk S. Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia. J Antimicrob Chemother. 1998;41(B):75-80.
Hatipoglu ON, Tasan Y. A comparative efficacy and safety study of clarithromycin, roxithromycin and erythromycin stearate in mild pneumonia. Yonsei Med J. 2000;41(3):340-4.
Kaku M, Kohno S, Koga H, Ishida K, Hara K. Efficacy of roxithromycin in the treatment of Mycoplasma pneumonia. Chemotherapy. 1995;41(2):149-52.
Juthong S, Eiamsa-ard S. Roxithromycin as Anti-Inflammatory Drug Improves Clinical Outcomes in Adult Patients with Bronchiectasis: A Double-Blinded Randomized, Placebo-Controlled Pilot Clinical Trial. J Health Sci Med Res. 2019;22;37(3):229-36.
Koh YY, Lee MH, Sun YH, Sung KW, Chae JH. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J. 1997;10(5):994-9.
Tatsis G, Tsoukalas G, Boulbasakos G, Platsouka E, Anagnostopoulou M, Pirounaki M, et al. Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections. J Antimicrob Chemother. 1998;41(B):69-73.
Marsac JH. An international clinical trial on the efficacy and safety of roxithromycin in 40,000 patients with acute community-acquired respiratory tract infections. Diagn Microbiol Infect Dis. 1992;15(4):81S-4S.
Lousbergh D, Jochems G, Everaert L, Puttemans M. Roxithromycin versus amoxicillin-clavulanic acid in the treatment of respiratory tract infections. Diagn Microbiol Infect Dis. 1992;15(4):91S-5S.
Cooper BC, Mullins PR, Jones MR, Lang SD. Clinical efficacy of roxithromycin in the treatment of adults with upper and lower respiratory tract infection due to Haemophilus influenzae: a meta-analysis of 12 clinical studies. Drug Investigation. 1994;7:299-314.
